Related Experiment Videos
Microalbuminuria in diabetes
1Divisione Medicina I, Istituto Scientifico San Raffaele, Milano, Italy. ruggero.mangili@hsr.it
Abstract:
Microalbuminuria is still the only early abnormality of the diabetic kidney that has an established prognostic value. Microalbuminuria evolves into clinical nephropathy and renal failure in a majority of cases of insulin-dependent diabetic patients, and is defined by the detection of urinary albumin excretion rates of 20-200 microg/min in timed urine collections. The occurrence of microalbuminuria at rates of 5-27 % of non-proteinuric patients and cost-benefit considerations justify the screening for microalbuminuria in diabetic outpatient clinics. Both near-normalisation of glycaemic control and treatment with ACE-inhibitors are indicated in patients with insulin-dependent diabetes to correct the progression of micro- to macroalbuminuria. Other therapeutic perspectives are being considered, but the current notion that the available therapies may not arrest the course of nephropathy at this stage suggests that earlier interventions may be required. Prevention of microalbuminuria and overt nephropathy may require a primary approach to the subset of patients with a genetic predisposition to this complication, and several studies (candidate gene or genomic scan with microsatellite probes) now address the chromosomal loci and the nature of the genes that may be involved.
Insights
Screening for microalbuminuria (early diabetic kidney abnormality) is crucial in diabetic patients. Early interventions, including glycemic control and ACE inhibitors, are vital to prevent progression to renal failure.
Area of Science:
- Nephrology
- Endocrinology
- Diabetology
Background:
- Microalbuminuria is the sole early indicator of diabetic kidney disease with prognostic significance.
- It progresses to clinical nephropathy and renal failure in most insulin-dependent diabetes patients.
- Defined by urinary albumin excretion rates of 20-200 microg/min.
Purpose of the Study:
- To highlight the prognostic value of microalbuminuria in diabetic kidney disease.
- To emphasize the need for screening in diabetic outpatient clinics.
- To discuss current and future therapeutic strategies.
Main Methods:
- Review of existing literature on microalbuminuria.
- Analysis of prevalence rates (5-27% in non-proteinuric patients).
- Consideration of cost-benefit for screening.
Main Results:
- Microalbuminuria screening is justified due to its prevalence and prognostic value.
- Near-normalization of glycemic control and ACE-inhibitor treatment can slow progression.
- Current therapies may not halt nephropathy, suggesting a need for earlier intervention.
Conclusions:
- Early detection and intervention are key to managing diabetic kidney disease.
- Further research into genetic predispositions is needed for primary prevention.
- Future strategies may focus on genetic factors for earlier intervention.